The Hypertension in Diabetes Study (HDS): A catalyst for change

Diabetic Medicine

Volumn 25, Issue SUPPL. 2, 2008, Pages 13-19

  Williams, B ^a,b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Diabetes; Hypertension; UKPDS

Indexed keywords

ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PERINDOPRIL; PLACEBO; SULFONYLUREA; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIET THERAPY; FOLLOW UP; GLYCEMIC CONTROL; HIGH RISK POPULATION; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PUBLICATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK MANAGEMENT;

ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 47649120594     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2008.02506.x     Document Type: Review

References (23)

1. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. Br Med J 1998 317 : 703 713.
2. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 39. Br Med J 1998 317 : 713 720.
3. Hypertension in Diabetes Study Group. HDS 1: prevalence of hypertension in newly presenting Type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993 11 : 309 317.
4. Hypertension in Diabetes Study Group. HDS 2: increased risk of cardiovascular complications in hypertensive Type 2 diabetic patients. J Hypertens 1993 11 : 319 325.
5. Garcia MJ, McNamara PM, Gordon T, Kannel WP. Morbidity and mortality in diabetics in the Framingham population. Sixteen-year follow-up study. Diabetes 1974 23 : 105 111.
6. Curb JD, Pressel SL, Cutler JA, Savage P, Applegate WB, Black H et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. J Am Med Assoc 1996 276 : 1886 1892.
7. Gaede P, Vedel P, Larsn N, Jensen GV, Parving HH, Pederson O. Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N. Eng J Med 2003 348 : 383 393.
8. Gaede P, Lund-Andersen H, Parving HH, Pederson O. Effect of a multifactorial intervention on mortality in Type 2 diabetes. N Eng J Med 2008 358 : 580 591.
9. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005 165 : 1410 1419.
10. Williams B. The unique vulnerability of diabetic subjects to hypertensive injury. In : Williams B, ed. Hypertension in Diabetes. London andNew York : Martin Dunitz Publisher, 2003 : 99 108.
11. Lindholm LH, Ibsen H, Dahlöff B, Devereox RB, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 359 : 1004 1010.
12. Dahlöff B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 366 : 895 906.
13. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000 355 : 253 259.
14. The ALLHAT Officers Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). J Am Med Assoc 2002 288 : 2981 2997.
15. Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB et al. for the ALLHAT Collaborative Research Group. Clinical outcomes in antihypertensive treatment of Type 2 diabetes, impaired fasting glucose concentration, and normoglycemia. Arch Intern Med 2005 165 : 1401 1409.
16. Mahboob-Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT, Whelton PK et al. for the ALLHAT Collaborative Research Group. Renal outcomes in high-risk hypertensivepatients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic. Arch Intern Med 2005 165 : 936 946.
17. Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua S, Weber M et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens 2006 24 : 2163 2168.
18. Parving HH, Lehnert H, Bröchner-Morteasen J, Gomis R, Andersen S, Arner P, for the Irbesartan in Patients with Type 2 Diabetes Microalbuminuria Study Group. The effect of Irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N Eng J Med 2001 870 : 78.
19. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al. Renoprotective effect of the angiotensin-receptor antagonist Irbesartan in patients with nephropathy due to Type 2 diabetes. N Eng J Med 2001 345 : 851 860.
20. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH et al. for the RENAAL Study Investigators. Effects of Losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Eng J Med 2001 345 : 861 869.
21. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with Type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007 370 : 829 840.
22. Williams B. The year in hypertension. J Am Coll Cardiol 2008 51 : 1803 1817.
23. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Design and methods. Am J Cardiol 2007 99 : S21 S33.